Endo International PLC (ENDP) Given Sell Rating at Mizuho
A number of other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. reaffirmed an overweight rating and set a $40.00 price objective on shares of Endo International PLC in a report on Tuesday, July 26th. Goldman Sachs Group Inc. began coverage on Endo International PLC in a research report on Monday, June 6th. They set a neutral rating and a $20.00 target price for the company. Zacks Investment Research upgraded Endo International PLC from a sell rating to a hold rating in a research report on Wednesday, July 20th. Morgan Stanley set a $15.00 price target on Endo International PLC and gave the stock a hold rating in a research report on Friday, August 5th. Finally, Vetr upgraded Endo International PLC from a buy rating to a strong-buy rating and set a $19.14 price target for the company in a research report on Monday, August 1st. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. Endo International PLC has an average rating of Hold and an average target price of $39.32.
Shares of Endo International PLC (NASDAQ:ENDP) traded down 0.172% during midday trading on Thursday, reaching $20.894. 3,012,059 shares of the company’s stock traded hands. Endo International PLC has a one year low of $12.56 and a one year high of $72.85. The stock’s 50-day moving average price is $21.48 and its 200 day moving average price is $21.28. The firm’s market capitalization is $4.65 billion.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.12. Endo International PLC had a negative net margin of 25.90% and a positive return on equity of 15.54%. The business earned $921 million during the quarter, compared to analyst estimates of $873.50 million. During the same period last year, the firm posted $1.08 EPS. The company’s revenue was up 25.3% on a year-over-year basis. On average, equities research analysts expect that Endo International PLC will post $4.56 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in ENDP. State Street Corp increased its position in Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock valued at $147,021,000 after buying an additional 805,101 shares during the last quarter. Geode Capital Management LLC increased its position in Endo International PLC by 0.9% in the first quarter. Geode Capital Management LLC now owns 1,759,167 shares of the company’s stock valued at $49,422,000 after buying an additional 15,173 shares during the last quarter. RS Investment Management Co. LLC increased its position in Endo International PLC by 0.4% in the second quarter. RS Investment Management Co. LLC now owns 1,374,185 shares of the company’s stock valued at $21,424,000 after buying an additional 6,132 shares during the last quarter. Heartland Advisors Inc. bought a new position in Endo International PLC during the second quarter valued at $15,627,000. Finally, Quantitative Investment Management LLC increased its position in Endo International PLC by 166.2% in the second quarter. Quantitative Investment Management LLC now owns 654,800 shares of the company’s stock valued at $10,208,000 after buying an additional 408,800 shares during the last quarter. 96.64% of the stock is owned by institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.